WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Various Folk Cultural Activities Held to Celebrate Lantern Festival in ChinaPeony Cultural Tourism Festival Kicks off in Wuding, SW China's YunnanSpring Campus Job Fair for Graduates of 2023 Held in Harbin, NE ChinaChinese Aviation History Museum Takes off in BeijingChina Focus: ShenzhouHexi District of Tianjin Sets up University for Senior CitizensChina's 10th National Public Ice and Snow Season launchedHighlights of 2023 Chinese Table Tennis Super LeagueSpinning Top Competition Held to Celebrate Upcoming Int'l Women's Day in S China's GuangxiHalf of China's Population Aged 65 to 69 Use Smartphones: Survey